{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:53:39Z","timestamp":1784886819357,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.intimp.2023.109953","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T13:18:30Z","timestamp":1680527910000},"page":"109953","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis"],"prefix":"10.1016","volume":"118","author":[{"given":"Gabriel","family":"Sosne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2023.109953_b9001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/exer.2001.1125","article-title":"Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury","volume":"74","author":"Sosne","year":"2002","journal-title":"Exp Eye Res."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.109953_b9002","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1517\/14712598.2015.1011617","article-title":"Advances in the basic and clinical applications of thymosin \u03b24","volume":"15","author":"Goldstein","year":"2015","journal-title":"Expert Opin Biol Ther."},{"issue":"7","key":"10.1016\/j.intimp.2023.109953_b9003","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1167\/iovs.04-1368","article-title":"Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury","volume":"46","author":"Sosne","year":"2005","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.109953_b9004","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1167\/iovs.15-16890","article-title":"Primary Mechanisms of Thymosin \u03b24 Repair Activity in Dry Eye Disorders and Other Tissue Injuries","volume":"56","author":"Sosne","year":"2015","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.109953_b9005","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE\u2122) model","volume":"20","author":"Sosne","year":"2015","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.intimp.2023.109953_b9006","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.vh.2016.04.012","article-title":"Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases","volume":"102","author":"Sosne","year":"2016","journal-title":"Vitam Horm."},{"issue":"8","key":"10.1016\/j.intimp.2023.109953_b9007","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/pr2004055","article-title":"Quantitative iTRAQ analysis of retinal ganglion cell degeneration after optic nerve crush","volume":"10","author":"Magharious","year":"2011","journal-title":"J Proteome Res."},{"issue":"14","key":"10.1016\/j.intimp.2023.109953_b9008","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1096\/fj.03-0121fje","article-title":"The actin binding site on thymosin beta4 promotes angiogenesis","volume":"17","author":"Philp","year":"2003","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.intimp.2023.109953_b9009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1523-1747.1999.00708.x","article-title":"Thymosin beta4 accelerates wound healing","volume":"113","author":"Malinda","year":"1999","journal-title":"J Invest Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109953_b9010","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1096\/fj.09-142307","article-title":"Biological activities of thymosin beta4 defined by active sites in short peptide sequences","volume":"24","author":"Sosne","year":"2010","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.intimp.2023.109953_b9011","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1096\/fj.10-169417","article-title":"Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling","volume":"25","author":"Freeman","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2023.109953_b9012","doi-asserted-by":"crossref","unstructured":"Yang X, Heitman LH, IJzerman AP, van der Es D. Molecular probes for the human adenosine receptors. Purinergic Signal. 2021 Mar;17(1):85-108. doi: 10.1007\/s11302-020-09753-8. Epub 2020 Dec 12. PMID: 33313997; PMCID: PMC7954947.","DOI":"10.1007\/s11302-020-09753-8"},{"key":"10.1016\/j.intimp.2023.109953_b9013","doi-asserted-by":"crossref","unstructured":"Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007 Apr; 84(4):663\u20139. doi: 10.1016\/j.exer.2006.12.004. Epub 2007 Jan 23. PMID: 17254567; PMCID: PMC2211446.","DOI":"10.1016\/j.exer.2006.12.004"},{"key":"10.1016\/j.intimp.2023.109953_b9014","doi-asserted-by":"crossref","unstructured":"Qiu P, Wheater MK, Qiu Y, Sosne G. Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J. 2011 Jun; 25(6):1815\u201326. doi: 10.1096\/fj.10-167940. Epub 2011 Feb 22. PMID: 21343177; PMCID: PMC3101037.","DOI":"10.1096\/fj.10-167940"},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9015","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1038\/s41598-017-03782-x","article-title":"Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling","volume":"7","author":"Kim","year":"2017","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.intimp.2023.109953_b9017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/eci.12048","article-title":"Thymosin \u03b24 protects C57BL\/6 mice from bleomycin-induced damage in the lung","volume":"43","author":"Conte","year":"2013","journal-title":"Eur J Clin Invest."},{"issue":"4","key":"10.1016\/j.intimp.2023.109953_b9018","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbrc.2017.09.156","article-title":"Thymosin \u03b24 attenuates liver fibrosis via suppressing Notch signaling","volume":"493","author":"Hong","year":"2017","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.intimp.2023.109953_b9019","doi-asserted-by":"crossref","unstructured":"Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin \u00df4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022 Dec 29;24(1):554. doi: 10.3390\/ijms24010554. PMID: 36613994; PMCID: PMC9820614.","DOI":"10.3390\/ijms24010554"},{"key":"10.1016\/j.intimp.2023.109953_b9020","doi-asserted-by":"crossref","unstructured":"Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond). 2021 Apr; 35(4):1084\u20131101. doi: 10.1038\/s41433-020-01339-3. Epub 2021 Jan 7. Erratum. In: Eye (Lond). 2021 Oct; 35(10):2908. PMID: 33414529; PMCID: PMC8102486.","DOI":"10.1038\/s41433-020-01339-3"},{"issue":"18","key":"10.1016\/j.intimp.2023.109953_b9021","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.3390\/ijms21186840","article-title":"Antimicrobial Effects of Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy in Pseudomonas aeruginosa Induced Keratitis","volume":"21","author":"Carion","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.109953_b9022","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1096\/fj.201701502R","article-title":"Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis","volume":"32","author":"Carion","year":"2018","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.intimp.2023.109953_b9023","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001352","article-title":"Lipopolysaccharide from biofilm-forming Pseudomonas aeruginosa PAO1 induces macrophage hyperinflammatory responses","volume":"70","author":"Wang","year":"2021","journal-title":"J Med Microbiol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109953_b9024","article-title":"Strategies for Zinc Uptake in Pseudomonas aeruginosa at the Host-Pathogen Interface","volume":"8","author":"Wang","year":"2021","journal-title":"Front Microbiol."},{"key":"10.1016\/j.intimp.2023.109953_b9025","unstructured":"Byrd LB, Martin N. Corneal Ulcer. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan\u2013. PMID: 30969511."},{"issue":"103","key":"10.1016\/j.intimp.2023.109953_b9026","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.colsurfb.2012.10.056","article-title":"Eudragit RL 100-based nanoparticulate system of aceclofenac for ocular delivery","volume":"1","author":"Katara","year":"2013","journal-title":"Colloids Surf B Biointerfaces."},{"issue":"7","key":"10.1016\/j.intimp.2023.109953_b9028","first-page":"644","article-title":"Corneal ulcers in a tertiary hospital in Africa","volume":"102","author":"Ezegwui","year":"2010","journal-title":"J Natl Med Assoc."},{"key":"10.1016\/j.intimp.2023.109953_b9029","article-title":"Clinical and Microbiological Spectra and Therapeutic Outcomes of Polymicrobial Keratitis","author":"Rathi","year":"2022","journal-title":"Cornea."},{"key":"10.1016\/j.intimp.2023.109953_b9030","doi-asserted-by":"crossref","unstructured":"Wong CA, Galvis V, Tello A, Villareal D, Rey JJ. Susceptibilidad antibi\u00f3tica in vitro a fluoroquinolonas [In vitro antibiotic susceptibility to fluoroquinolones]. Arch Soc Esp Oftalmol. 2012 Mar;87(3):72-8. Spanish. doi: 10.1016\/j.oftal.2011.06.023. Epub 2011 Dec 29. PMID: 22423655.","DOI":"10.1016\/j.oftal.2011.06.023"},{"issue":"8","key":"10.1016\/j.intimp.2023.109953_b9031","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ophtha.2012.01.052","article-title":"Risk factors for moderate and severe microbial keratitis in daily wear contact lens users","volume":"119","author":"Stapleton","year":"2012","journal-title":"Ophthalmology."},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9032","first-page":"6","article-title":"Contact lens related corneal ulcer","volume":"5","author":"Loh","year":"2010","journal-title":"Malays Fam Physician."},{"issue":"3","key":"10.1016\/j.intimp.2023.109953_b9034","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00006324-199603000-00009","article-title":"Effects of hypoxia and hypercapnia on contact lens-induced corneal acidosis","volume":"73","author":"Rivera","year":"1996","journal-title":"Optom Vis Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9035","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2018.10.018","article-title":"American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Bacterial Keratitis Preferred Practice Pattern\u00ae","volume":"126","author":"Lin","year":"2019","journal-title":"Ophthalmology."},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1099\/jmm.0.001110","article-title":"Pseudomonas aeruginosa and microbial keratitis","volume":"69","author":"Hilliam","year":"2020","journal-title":"J Med Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2003.10.002","article-title":"Corneal response to Pseudomonas aeruginosa infection","volume":"23","author":"Hazlett","year":"2004","journal-title":"Prog Retin Eye Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109953_b9038","article-title":"Potential new fluoroquinolone treatments for suspected bacterial keratitis","volume":"7","author":"Herbert","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109953_b9039","first-page":"534","article-title":"Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence","volume":"37","author":"O'Callaghan","year":"1996","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"10.1016\/j.intimp.2023.109953_b9040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3390\/microorganisms7090281","article-title":"Pseudomonas aeruginosa Keratitis: Protease IV and PASP as Corneal Virulence Mediators","volume":"7","author":"O'Callaghan","year":"2019","journal-title":"Microorganisms."},{"issue":"5","key":"10.1016\/j.intimp.2023.109953_b9041","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/ICO.0b013e31825a6d9a","article-title":"Bovine pericardium membrane (tutopatch) combined with solid platelet-rich plasma for the management of perforated corneal ulcers","volume":"32","author":"Alio","year":"2013","journal-title":"Cornea."},{"issue":"12","key":"10.1016\/j.intimp.2023.109953_b9042","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/ICO.0b013e3181d2de91","article-title":"Infectious keratitis treated with corneal crosslinking","volume":"29","author":"Makdoumi","year":"2010","journal-title":"Cornea."},{"issue":"4","key":"10.1016\/j.intimp.2023.109953_b9043","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1167\/iovs.04-0542","article-title":"Internalization of Pseudomonas aeruginosa is mediated by lipid rafts in contact lens-wearing rabbit and cultured human corneal epithelial cells","volume":"46","author":"Yamamoto","year":"2005","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"10.1016\/j.intimp.2023.109953_b9044","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1167\/iovs.07-0993","article-title":"Disruption of CFTR-dependent lipid rafts reduces bacterial levels and corneal disease in a murine model of Pseudomonas aeruginosa keratitis","volume":"49","author":"Zaidi","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"7","key":"10.1016\/j.intimp.2023.109953_b9045","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1365-2958.1991.tb01903.x","article-title":"Mucoid Pseudomonas aeruginosa in cystic fibrosis: signal transduction and histone-like elements in the regulation of bacterial virulence","volume":"5","author":"Deretic","year":"1991","journal-title":"Mol Microbiol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109953_b9046","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1164\/rccm.201705-1043SO","article-title":"Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection","volume":"197","author":"Curran","year":"2018","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.intimp.2023.109953_b9047","doi-asserted-by":"crossref","unstructured":"Schiumarini D, Loberto N, Mancini G, Bassi R, Giussani P, Chiricozzi E, Samarani M, Munari S, Tamanini A, Cabrini G, Lippi G, Dechecchi MC, Sonnino S, Aureli M. Evidence for the Involvement of Lipid Rafts and Plasma Membrane Sphingolipid Hydrolases in Pseudomonas aeruginosa Infection of Cystic Fibrosis Bronchial Epithelial Cells. Mediators Inflamm. 2017 2017:1730245. doi: 10.1155\/2017\/1730245. Epub 2017 Dec 3. PMID: 29333001; PMCID: PMC5733190.","DOI":"10.1155\/2017\/1730245"},{"key":"10.1016\/j.intimp.2023.109953_b9048","doi-asserted-by":"crossref","unstructured":"Marquart ME, O'Callaghan RJ. Infectious keratitis: secreted bacterial proteins that mediate corneal damage. J Ophthalmol. 2013 2013:369094. doi: 10.1155\/2013\/369094. Epub 2013 Jan 8. PMID: 23365719; PMCID: PMC3556867.","DOI":"10.1155\/2013\/369094"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923002734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:01:47Z","timestamp":1761588107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923002734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":45,"alternative-id":["S1567576923002734"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109953","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109953","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109953"}}